Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Aldose reductase inhibitors from Terumo

Aug. 30, 1996

Sankyo reports novel hypoglycemic agents

Aug. 30, 1996

Positive efficacy/safety profile for maximal-dose sulfonylurea therapy reported

Aug. 30, 1996

Beta3-adrenoceptor agonists described by Dainippon

Aug. 30, 1996

Cangene and Cheil Jedang sign Leucotropin agreement

Aug. 30, 1996

CCK antagonists from Warner-Lambert

Aug. 30, 1996

NGD-95-1 demonstrates safety in phase I

Aug. 30, 1996

More squalene synthase inhibitors from Pfizer

Aug. 30, 1996

Xenical to be marketed in 1997

Aug. 30, 1996

SDZ-266806: A novel squalene synthase inhibitor

Aug. 30, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.